HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

avoralstat

Also Known As:

3-(2-((4-carbamimidoylphenyl)carbamoyl)-4-ethenyl-5-methoxyphenyl)-6-((cyclopropylmethyl)carbamoyl)pyridine-2-carboxylic acid; BCX-4161; BCX4161

Networked: 4 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Collis, P: 2 articles (09/2018 - 12/2016)
2.	Cornpropst, M: 2 articles (09/2018 - 12/2016)
3.	Fang, L: 2 articles (09/2018 - 12/2016)
4.	Sheridan, W P: 2 articles (09/2018 - 12/2016)
5.	Bassuk, Alexander G: 1 article (01/2021)
6.	Li, Kun: 1 article (01/2021)
7.	Mahajan, Vinit B: 1 article (01/2021)
8.	McCray, Paul B: 1 article (01/2021)
9.	Ortiz, Miguel E: 1 article (01/2021)
10.	Parsons, Dylan E: 1 article (01/2021)

Related Diseases

1.	Angioedema 09/01/2018 - "Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1-INH-HAE, it provided evidence of shortened angioedema episodes and improved QoL in the avoralstat 500 mg treatment group compared with placebo." 09/01/2018 - "Using the Angioedema Quality of Life Questionnaire (AE-QoL), improved QoL was observed for the avoralstat 500 mg group compared with placebo. "
2.	Hereditary Angioedemas 09/01/2018 - "Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study." 01/01/2016 - "Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat." 12/01/2016 - "Avoralstat is a potent small-molecule oral plasma kallikrein inhibitor under development for treatment of hereditary angioedema (HAE). "
3.	Abdominal Pain (Pain, Abdominal) 12/01/2016 - "Four moderate severity AEs were reported in two subjects; syncope after a single 250 mg dose (one subject) and abdominal pain, back pain, and eczema after multiple doses of 800 mg avoralstat (one subject). "
4.	Weight Loss (Weight Reduction) 01/01/2021 - "In an in vivo proof of principle, avoralstat significantly reduced lung tissue titers and mitigated weight loss when administered prophylactically to mice susceptible to SARS-CoV-2, indicating its potential to be repositioned for coronavirus disease 2019 (COVID-19) prophylaxis in humans."
5.	Syncope (Fainting) 12/01/2016 - "Four moderate severity AEs were reported in two subjects; syncope after a single 250 mg dose (one subject) and abdominal pain, back pain, and eczema after multiple doses of 800 mg avoralstat (one subject). "

Related Drugs and Biologics

1.	Plasma Kallikrein
2.	Kallikreins (Kallikrein)
3.	Trypsin Inhibitors
4.	Antipain
5.	PCI-27483